Recombinant Sendai virus vectors for activated T lymphocytes

• Published in: Gene therapy Vol. 10; no. 16; pp. 1381 - 1391
• Main Authors: Okano, S, Yonemitsu, Y, Nagata, S, Sata, S, Onimaru, M, Nakagawa, K, Tomita, Y, Kishihara, K, Hashimoto, S, Nakashima, Y, Sugimachi, K, Hasegawa, M, Sueishi, K
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.08.2003; Nature Publishing Group
• Subjects: Animals; Antigens; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Care and treatment; Cell activation; Cell Biology; Cell Line; Centrifugation; Cytoplasm; Expression vectors; Female; Fundamental and applied biological sciences. Psychology; Gene Expression; Gene Therapy; Genetic aspects; Genetic Therapy - methods; Genetic Vectors - administration & dosage; Genetic Vectors - genetics; Green fluorescent protein; Green Fluorescent Proteins; Health aspects; Human Genetics; Humans; Immunologic diseases; Immunotherapy, Adoptive - methods; Luminescent Proteins - genetics; Lymphocyte Activation; Lymphocytes; Lymphocytes T; Methods; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Molecular and cellular biology; Nanotechnology; Physiological aspects; Polybrene; Protamine sulfate; Receptors, Antigen, T-Cell - genetics; Receptors, Antigen, T-Cell - metabolism; research-article; Sendai virus - genetics; T cells; T-Lymphocytes - metabolism; Time Factors; Canada; Japan; gene therapy; Sendai virus vector; enhanced green fluorescent protein gene; T cells; Genetics

T-lymphocyte-directed gene therapy has potential as a treatment of subjects with immunological disorders. One current limitation of this therapeutic strategy is low gene transfer efficiency, even when complex procedures are used. We report herein that a recombinant Sendai virus vector (SeV) was able...